Table 1.

Clinical Characteristics^*

	N=12
Age (days)	59 (0.0, 574)
Gestational age (weeks)	39 (27, 39)
Weight (kg)	3.7 (2.9, 9.6)
Birth weight (kg)	3 (2.4, 4.3)
Male, n (%)	5 (42)
Race, n (%)
White	6 (50)
African American	6 (50)
Diagnosis, n (%)
Cardiomyopathy	4 (34)
Pulmonary hypertension	3 (25)
Congenital heart disease	3 (25)
Congenital diaphragmatic hernia	1 (8)
Respiratory failure	1 (8)
Serum creatinine (mg/dL)†	0.5 (0.2, 1.6)
ECMO support, n (%)
Veno-arterial	11 (92)
Veno-venous	1 (8)
ECMO circuit configuration, n (%)
S3	8 (67)
Cardiohelp	4 (33)
Micafungin indication n (%)
Prophylaxis	11 (92)
Therapy	1 (8)
Micafungin dosing (mg/kg/day)	4 (4, 8)
Duration of therapy (days)	4 (2, 8)
Duration of ECMO support at time of first micafungin dosing (days)	4 (2, 10)
Number of PK samples per infant	11 (6, 14)
PK samples obtained around, n (%)
Dose 1-2	12 (100)
Dose 4-5	6 (50)

^*Results are expressed as median (range) unless otherwise specified

^†Median serum creatinine for each subject over the study period.